Peptides
TB-500 Fragment
Also called TB-500 (FRAG) · LKKTETQ
The TB-500 fragment is a small piece of thymosin beta-4. Researchers study both the fragment and what it breaks down into; these can have different effects in laboratory experiments.
At a glance
The available facts are above. Sources and model details are below.
Model details: TB-500 Fragment · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
The 2024 study examines human-serum/enzyme incubations and rat urine. Metabolite detection to 72 h is not the parent plasma half-life; legacy 0.96 h remains an assumption.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.96 hours
- Absorption half-life assumed
- 0.24 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- No human parent-peptide systemic calibration established in reviewed sources.
- Ac-LKKTE wound-assay activity is a metabolite effect, not a blood exposure endpoint.
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
The 2024 study examines human-serum/enzyme incubations and rat urine. Metabolite detection to 72 h is not the parent plasma half-life; legacy 0.96 h remains an assumption.
tb-500-frag-relative-timing-2026-10 · version 1
Sources Labels, studies and notes behind this guide
Notes on the quick facts
- Relative timing half-life
- Timing used in the relative curve. Source and route details are in Model details.
- 1. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
The 2024 study examines human-serum/enzyme incubations and rat urine. Metabolite detection to 72 h is not the parent plasma half-life; legacy 0.96 h remains an assumption.
Related compounds and examples
Related compounds
BPC-157
Why people consider BPC-157 for tendon, ligament, muscle and gut recovery, plus oral versus injected forms, expected timing and practical trade-offs.
TB-500 (Thymosin Beta-4)
Why people research TB-500 for tendon, muscle and joint recovery, how reported courses are described, and what to know when comparing it with BPC-157.
ARA-290 (Cibinetide)
ARA-290 for nerve symptoms: research doses, 28-day studies and realistic expectations for neuropathy.